Dr. Bradley D. Torphy, M.D.

Medicare patients and services

Medicare patients, 2024

68

Services billed

10,453

Patients’ average age

65

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 8 companies reported 237 payments worth $206,381 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Illinois →

Industry-funded research

Named as a principal investigator on 14 industry-funded studies in 2025, from 7 companies. The companies reported $289,033 in research payments for these studies, mostly to the institutions running them.

• A Real-World Retrospective Chart Review to Evaluate Effectiveness and Safety of Fremanezumab in Migraine Patients with a Body Mass index
  Teva Pharmaceuticals USA, Inc.
• IIT-2020-11028//Ubrelvy Efficacy and Safety in the Treatment of Acute Migraine in Patients Currently Treated with CGRP monoclonal antibodies (CGRPmAbs)(A23-256)
  AbbVie Inc.
• A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
  Eli Lilly and Company · Terminated · NCT04396574
• A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications
  H. Lundbeck A S
• A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
  Eli Lilly and Company · Terminated · NCT04396236
• Phase 3 multicenter randomized doubleblind group sequential placebocontrolled study to assess efficacy and safety of rimegepant for the treatment of migraine with or without aura in children and adolescents 6 to 18 …
  Pfizer Inc.
• Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)
  AbbVie Inc. · Enrolling by invitation · NCT05127954
• A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
  Ipsen Innovation · Active, not recruiting · NCT06047444
• Phase 3 multicenter openlabel study to assess the longterm safety and tolerability of rimegepant for the acute treatment of migraine with or without aura in children and adolescents 6 to 18 years of age
  Pfizer Inc.
• A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
  Ipsen Innovation · Active, not recruiting · NCT06047457

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Family Medicine clinicians in Chicago

• Nikka Abaricia, MD
• Mohemmed Abbas
• Ahmed T. Abdelkader, MD
• Ahmad A. Abdl-haleem, DO
• Abdulmassih Abdulmassih, M.D.
• Olalekan M. Abimbola, MD
• Olga L. Abreu Lopez
• Olatokunbo Adegboro, MD